Market is forward looking…
In theory, CYC FDA approval opened the US market to them.
I would say many new investors have a taken a short term position for a quick gain upon approval.
Of course if Sofdra sales are strong in the US, then the share price will rise accordingly. What I mean to say is I can’t picture a massive SP jump on approval.
DXB is a bit different in that the licensing announcement came suddenly, which resulted in a massive jump on the day as investors scrambled to get in…
Just my thoughts, no offence, could be wrong etc
Market is forward looking…In theory, CYC FDA approval opened the...
-
- There are more pages in this discussion • 73 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
0.025(7.46%) |
Mkt cap ! $567.0M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.5¢ | 33.3¢ | $14.94M | 42.66M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 112268 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 276101 | 7 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |